Tyra Biosciences (TYRA) stock is back in focus after first quarter results showed a wider net loss, a strong cash position, ongoing Phase 2 trials for dabogratinib and fresh institutional buying interest.

The stock has cooled off in recent sessions, with the share price down 5.3% over the last day and 5.0% over the past month, but a 26.1% year to date share price return and a very strong 1 year total shareholder return of 238.5% point to momentum that has built rapidly around the pipeline, conference updates and fresh institutional interest.

If Tyra’s clinical and earnings updates have your attention, it can also be useful to see what else is moving in biotech. You can scan other healthcare-focused AI opportunities via our 29 healthcare AI stocks

With Tyra still loss making but holding US$383.5 million in cash and trading below the average analyst price target, the key question for you is simple: is there still upside here, or has the market already priced in future growth?

Preferred Price-To-Book Multiple Of 5.2x: Is It Justified?

Tyra Biosciences trades on a P/B of 5.2x at a last close of $33.78, which is rich against the broader US biotech group but lower than its direct peer set.

P/B compares the market value of the company with the book value of its net assets. It is often used for early stage or loss making biotechs where traditional earnings based ratios are less useful. For a business with no meaningful revenue yet and an ongoing net loss of $131.11 million, a higher P/B typically implies investors are placing a premium on the drug pipeline, intellectual property and cash on the balance sheet.

Here, the 5.2x P/B is more than double the US biotechs industry average of 2.3x, which suggests the market is paying up relative to the wider sector. At the same time, it sits below the 7.3x peer average, so compared with closer comparables the stock is not at the top of the valuation range.

Result: Price-to-book ratio of 5.2x (ABOUT RIGHT)

However, the wider net loss of US$131.11 million and the fact that Tyra has no revenue yet mean that clinical or funding setbacks could quickly cool sentiment around the stock.

Next Steps

With the mix of enthusiasm and caution in this story, it helps to move quickly, review the data yourself, and decide where you stand based on the 2 key rewards and 3 important warning signs.

Ready For More Investment Ideas?

If Tyra has sharpened your focus, do not stop here. The next opportunity that fits your style could already be on the radar of our screeners.

• Target resilient companies that prioritise capital strength by reviewing our solid balance sheet and fundamentals stocks screener (46 results).
• Spot potential value opportunities before the crowd by scanning our 54 high quality undervalued stocks.
• Unearth future leaders that are not yet widely followed through our screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.